Optibrium appoints Professor Andy Black as non-executive Chair
Optibrium™, a developer of software for drug discovery, today announced the appointment of Professor Andy Black as non-executive Chair of its Board of Directors. Following the company’s recent investment from Kester Capital, the appointment will help to continue Optibrium’s strong commercial growth calling on Andy’s extensive experience in leading strategic expansion. This will include the…
FairJourney Biologics announces THE ANTIBODY SERIES 2022
Porto, Portugal –FairJourney Biologics SA, leader in the discovery and optimisation of antibodies, today announced, after the overwhelming success of the 2021 ANTIBODY SERIES conference, planning for a larger scale 2022 ANTIBODY SERIES is underway.
GammaDelta Therapeutics initiates first-in-human Phase 1 trial of GDX012 for treatment of acute myeloid leukaemia
London, UK, 15 Sept 2021: GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma…
Insightful Science acquires FCS Express, strengthening its leadership position as the Cloud for Scientific Discovery
Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has completed the transaction to acquire De Novo Software, the maker of FCS Express™. FCS Express is the fastest-growing flow cytometry data analysis solution in the industry.
Optibrium releases 3D ligand-based design module for StarDrop drug discovery software
Optibrium Ltd, a developer of software for drug discovery, has announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. StarDrop is used by more than 160 organisations worldwide, including many of the top global pharmaceutical companies. The release of StarDrop 7.1 further expands the platform’s…
Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces new appointments to its Scientific Advisory Board (SAB), reflecting the progress of the Therapeutics Division and Avacta’s transition to a clinical stage Company.
Avacta appoints Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces the appointment of Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division effective immediately.
FairJourney Biologics expands into new facilities in Porto, Portugal
FairJourney Biologics SA (FJB), leader in the discovery and optimisation of antibodies, announced it has relocated into a larger, newly purpose-built research center in Porto, Portugal. The new premises support the Company’s expansion and plans for further growth.
Avacta appoints Dr. Mark Goldberg as Non-Executive Director
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces the appointment of Dr Mark Goldberg as Non-executive Director to the Board with immediate effect.
ELRIG UK announces Drug Discovery 2021 event to host SLAS’s Innovation AveNEW
The European Laboratory Research & Innovation Group (ELRIG) UK has announced the programme details for Drug Discovery 2021, which will take place at the Exhibition Centre ACC in Liverpool, UK, from 19–20 October.
ERS Genomics and Cellular Engineering Technologies enter CRISPR/Cas9 license agreement
License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology
Avacta announces first patient dosed in AVA6000 Pro-Doxorubicin Phase I clinical trial
Cambridge and Wetherby... Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
FUJIFILM Irvine Scientific becomes sole worldwide distributor of Presagen’s Life Whisperer
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection.
Dotmatics to deliver the foundation for Croda’s R&D digital programme: artificial intelligence and data mining
Bishop’s Stortford, UK... Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Croda International Plc to implement its Research and Development (R&D) digital programme. Croda is the name behind the high-performance ingredients…
ERS Genomics and Japan SLC sign CRISPR/Cas9 licence agreement
Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models.
Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business
Oxford...Orbit Discovery Ltd, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million (USD) in funding.
Dotmatics announces support for AWS for Health initiative
Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, announced support for the AWS for Health initiative from Amazon Web Services (AWS) to improve laboratory efficiency and accelerate the pace of scientific innovation by facilitating more rapid data access, analysis and…
Mologic to become a ‘social enterprise’ after acquisition by social impact funders and investors
A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, is today announcing the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the…
H.E.L Group strengthens operations in North America
London, UK, 15 July 2021: H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, today announced that it has expanded its operations in North America, with the establishment of a West Coast hub in California, and a Central Region hub in Missouri.
Bio-Rad launches its Reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit in Europe
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
Avacta’s Diagnostic Division achieves ISO 13485 certification
Cambridge and Wetherby, UK, 14 July 2021: Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics division has achieved ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for…
Gyros Protein Technologies and Cygnus Technologies expand collaboration
Uppsala, Sweden, 07 July 2021: Gyros Protein Technologies (part of Mesa Labs’ Biopharmaceutical Development Division), a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the next phase of its on-going collaboration with Cygnus Technologies, a Maravai LifeSciences company, and the introduction of a new HEK 293 HCP…
Birmingham University and Nonacus partner to develop urine test for bladder cancer
Birmingham, UK, 01 July 2021: Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive test for bladder cancer.
ERS Genomics and Nippon Gene sign CRISPR/Cas9 licence agreement
Dublin, Ireland and Tokyo, Japan, 01 July 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and Nippon Gene Co Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive licence…
FairJourney Biologics introduces 'THE ANTIBODY SERIES' Conference
FairJourney Biologics SA (FJB), leaders in the discovery and optimization of antibodies, today announced the launch of the “THE ANTIBODY SERIES” - a one-day conference bringing together top experts in the antibody field to explore the latest innovation within antibody drug discovery.